Canaccord Genuity Maintains Buy on Exagen, Lowers Price Target to $9
Benzinga Newsdesk 7 hours ago
Analyst RatingsNewsPrice Target
Canaccord Genuity analyst Kyle Mikson maintains Exagen (NASDAQ:XGN) with a Buy and lowers the price target from $11 to $9.
Canaccord Genuity analyst Kyle Mikson maintains Exagen (NASDAQ:XGN) with a Buy and lowers the price target from $11 to $9.